Accordingly, the reduction of tumor cell proliferation, indicated by the Ki67 marker values, observed in tumor bearing mice treated with the mPGES-1 inhibitor, might be explained by the impairment of tumor blood supply, and by the direct inhibition of the proliferative signaling of EGF/EGFR pathway. This evidence concerns the gene EGFR and neoplasm.